215. Dummer R., Ascierto P. A., Gogas H. J., Arance A., Mandala M., Liszkay G., Garbe C., Schadendorf D., Krajsova I., Gutzmer R., Chiarion-Sileni V., Dutriaux C., de Groot J. W. B., Yamazaki N., Loquai C., Moutouh-de Parseval L. A., Pickard M. D., Sandor V., Robert C., Flaherty K. T. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial // Lancet Oncol. ‒ 2018. ‒ T. 19, № 5. ‒ C. 603-615.
216. Dummer R., Flaherty K. T., Robert C., Arance A., de Groot J. W. B., Garbe C., Gogas H. J., Gutzmer R., Krajsova I., Liszkay G., Loquai C., Mandala M., Schadendorf D., Yamazaki N., di Pietro A., Cantey-Kiser J., Edwards M., Ascierto P. A. COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma // J Clin Oncol. ‒ 2022.10.1200/JCO.21.02659. ‒ C. JCO2102659.
217. Dummer R., Queirolo P., Guijarro A. M. A., Hu Y., Wang D., Azevedo S. J., Robert C., Ascierto P. A., -Sileni V. C., Pronzato P., Spagnolo F., Mujika K., Liszkay G., Merino L. d. l. C., Tawbi H. A. Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study // Journal of Clinical Oncology. ‒ 2022. ‒ T. 40, № 16_suppl. ‒ C. 9515-9515.
218. Gutzmer R., Stroyakovskiy D., Gogas H., Robert C., Lewis K., Protsenko S., Pereira R. P., Eigentler T., Rutkowski P., Demidov L., Manikhas G. M., Yan Y., Huang K. C., Uyei A., McNally V., McArthur G. A., Ascierto P. A. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial // Lancet. ‒ 2020. ‒ T. 395, № 10240. ‒ C. 1835-1844.
219. McArthur G. A., Chapman P. B., Robert C., Larkin J., Haanen J. B., Dummer R., Ribas A., Hogg D., Hamid O., Ascierto P. A., Garbe C., Testori A., Maio M., Lorigan P., Lebbe C., Jouary T., Schadendorf D., O'Day S. J., Kirkwood J. M., Eggermont A. M., Dreno B., Sosman J. A., Flaherty K. T., Yin M., Caro I., Cheng S., Trunzer K., Hauschild A. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study // Lancet Oncol. ‒ 2014. ‒ T. 15, № 3. ‒ C. 323-32.
220. Scholtens A., Geukes Foppen M. H., Blank C. U., van Thienen J. V., van Tinteren H., Haanen J. B. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression // Eur J Cancer. ‒ 2015. ‒ T. 51, № 5. ‒ C. 642-52.
221. Sosman J. A., Kim K. B., Schuchter L., Gonzalez R., Pavlick A. C., Weber J. S., McArthur G. A., Hutson T. E., Moschos S. J., Flaherty K. T., Hersey P., Kefford R., Lawrence D., Puzanov I., Lewis K. D., Amaravadi R. K., Chmielowski B., Lawrence H. J., Shyr Y., Ye F., Li J., Nolop K. B., Lee R. J., Joe A. K., Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib // N Engl J Med. ‒ 2012. ‒ T. 366, № 8. ‒ C. 707-14.
222. Davies M. A., Saiag P., Robert C., Grob J. J., Flaherty K. T., Arance A., Chiarion-Sileni V., Thomas L., Lesimple T., Mortier L., Moschos S. J., Hogg D., Marquez-Rodas I., Del Vecchio M., Lebbe C., Meyer N., Zhang Y., Huang Y., Mookerjee B., Long G. V. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial // Lancet Oncol. ‒ 2017. ‒ T. 18, № 7. ‒ C. 863-873.
223. Long G. V., Hauschild A., Santinami M., Atkinson V., Mandala M., Chiarion-Sileni V., Larkin J., Nyakas M., Dutriaux C., Haydon A., Robert C., Mortier L., Schachter J., Schadendorf D., Lesimple T., Plummer R., Ji R., Zhang P., Mookerjee B., Legos J., Kefford R., Dummer R., Kirkwood J. M. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma // N Engl J Med. ‒ 2017. ‒ T. 377, № 19. ‒ C. 1813-1823.
224. Long G. V., Trefzer U., Davies M. A., Kefford R. F., Ascierto P. A., Chapman P. B., Puzanov I., Hauschild A., Robert C., Algazi A., Mortier L., Tawbi H., Wilhelm T., Zimmer L., Switzky J., Swann S., Martin A. M., Guckert M., Goodman V., Streit M., Kirkwood J. M., Schadendorf D. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial // Lancet Oncol. ‒ 2012. ‒ T. 13, № 11. ‒ C. 1087-95.
225. Schreuer M., Jansen Y., Planken S., Chevolet I., Seremet T., Kruse V., Neyns B. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial // Lancet Oncol. ‒ 2017. ‒ T. 18, № 4. ‒ C. 464-472.
226. Davidson G., Coassolo S., Kieny A., Ennen M., Pencreach E., Malouf G. G., Lipsker D., Davidson I. Dynamic Evolution of Clonal Composition and Neoantigen Landscape in Recurrent Metastatic Melanoma with a Rare Combination of Driver Mutations // J Invest Dermatol. ‒ 2019. ‒ T. 139, № 8. ‒ C. 1769-1778 e2.
227. Gerami P., Li G., Pouryazdanparast P., Blondin B., Beilfuss B., Slenk C., Du J., Guitart J., Jewell S., Pestova K. A highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms // Am J Surg Pathol. ‒ 2012. ‒ T. 36, № 6. ‒ C. 808-17.
228. Shain A. H., Joseph N. M., Yu R., Benhamida J., Liu S., Prow T., Ruben B., North J., Pincus L., Yeh I., Judson R., Bastian B. C. Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution // Cancer Cell. ‒ 2018. ‒ T. 34, № 1. ‒ C. 45-55 e4.
229. Takata M., Suzuki T., Ansai S., Kimura T., Shirasaki F., Hatta N., Saida T. Genome profiling of melanocytic tumors using multiplex ligation-dependent probe amplification (MLPA): Its usefulness as an adjunctive diagnostic tool for melanocytic tumors // J Dermatol Sci. ‒ 2005. ‒ T. 40, № 1. ‒ C. 51-7.